Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype

Leukemia and Lymphoma

Volumn 49, Issue 3, 2008, Pages 524-530

  Mi, Yingchang ^a   Xue, Yanping ^a   Yu, Wenjuan ^b   Liu, Shihe ^a   Zhao, Yaozhong ^a   Meng, Qingxiang ^c   Bian, Shougeng ^a   Wang, Jianxiang ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c PEKING UNIVERSITY   (China)

Author keywords

Chemotherapeutic approaches; Cytogenetics; Induction regimen; Leukemia myeloid acute; Neoplasia; Prognosis

Indexed keywords

CYTARABINE; DAUNORUBICIN; HOMOHARRINGTONINE; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CHINA; CONTROLLED STUDY; CYTOGENETICS; DISEASE FREE SURVIVAL; FEMALE; GENETIC RISK; HUMAN; KARYOTYPE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATIENT CODING; PATIENT SELECTION; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; REPEATED DRUG DOSE; RISK ASSESSMENT; SCHOOL CHILD; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHINA; CYTARABINE; CYTOGENETIC ANALYSIS; DAUNORUBICIN; FEMALE; HARRINGTONINES; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MITOXANTRONE; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 39749111813     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701836852     Document Type: Article

References (29)

1. Dillman, R. O., Davis, R. B., Green, M. R., Weiss, R. B., Gottlieb, A. J. and Caplan, S. (1991) A comparative study of two different doses of cytarabine for acute myeloid leukemia: A phase III trial of Cancer and Leukemia Group B. Blood, 78, pp. 2520-2526.
2. Bishop, J. F. (1997) The treatment of adult acute myeloid leukemia. Semin Oncol, 22, pp. 57-69.
3. Slovak, M. L., Kopecky, K. J., Cassileth, P. A., Harring, D. H., Theil, K. S. and Mohamed, A. (2000) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood, 96, pp. 4075-4083.
4. Wheatley, K., Burnett, A. K., Goldstone, A. H., Gray, R. G., Hann, I. M. and Harrison, C. J. (1999) A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukemia derived from the MRC AML 10 trial. Br J Hematol, 107, pp. 69-79.
5. Grimwade, D., Walker, H., Harrison, G., Oliver, F., Chatters, S. and Harrison, C. J. (2001) The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML 11 trial. Blood, 98, pp. 1312-1320.
6. Buchner, T., Hiddermann, W., Wormann, B., Loffler, H., Grassmann, W. and Haferlach, T. (1999) Double induction strategy for acute myeloid leukemia: The effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with Daunorubicin and 6-Thiogunine: A randomized trial by the German AML Cooperative Group. Blood, 93, pp. 4116-4124.
7. Schlenk, R. F., Benner, A., Hartmann, F., Valle, F del, Weber, C. and Pralle, H. (2003) Risk-adapted postremission therapy in acute myeloid leukemia: Results of the German multicenter AML HD93 treatment trial. Leukemia, 17, pp. 1521-1528.
8. Kantarjian, H. M., Talpaz, M., Santini, V., Murgo, A., Cheson, B. and O'Brien, S. M. (2001) Homoharringtonine: History, current research, and future directions. Cancer, 92, pp. 1591-1605.
9. Ni, D., Ho, D. H., Vijjeswarapu, M., Felix, E., Rhea, P. R. and Newman, R. A. (2003) Metabolism of homoharringtonine, a cytotoxic component of the evergreen plant Cephalotaxus harringtonia. J Exp Ther Oncol, 3, pp. 47-52.
10. Lou, Y., Jin, J., Xu, W., Yingjun, L., Jie, J., Weilai, X. and Xiangming, T. (2004) Homoharringtonine mediates myeloid cell apoptosis via upregulation of pro-apoptotic bax and inducing caspase-3-mediated cleavage of poly(ADP-ribose) polymerase (PARP). Am J Hematol, 76, pp. 199-204.
11. Bian, S., Wang, Z., Hao, Y., Yan, W., Yang, T. and Qian, L. (1988) Combination chemotherapy for acute nonlymphoblastic leukemia in adult: A comparison of HAT and D(A)AT protocols. Chin J Hematol, 9, pp. 449-452.
12. Bian, S., Hao, Y., Wang, Z., Yan, W., Yang, T. and Qian, L. (1990) Results of 91 acute nonlymphoblastic leukemia patients treated with intensive chemotherapy. Chin J Int Med, 29, pp. 22-25.
13. Bian, S., Hao, Y., Wang, Z., Qian, L., Yang, T. and Xue, Y. (1993) Study on chemotherapy of adult acute nonlymphoblastic leukemia: A comparison of short and long term effectiveness between HA and DA(T) regimens. Chin J Hematol, 14, pp. 59-62.
14. Xue, Y., Bian, S., Meng, Q., Mi, Y., Yang, D. and Zhang, Y. (1995) HAD combination chemotherapy for adult acute nonlymphoblastic leukemia. Chin J Hematol, 16, pp. 59-61.
15. Xue, Y., Bian, S., Zhao, Y., Mi, Y., Meng, Q. and Wang, M. (2002) Comparison of 4 groups triple-drug combination chemotherapy for adult acute nonlymphoblastic leukemia. Chin J Hematol, 23, pp. 33-34.
16. Slovak, M. L., Kopecky, K. J., Cassileth, P. A., Harrington, D. H., Theil, K. S. and Mohamed, A. (2000) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood, 96, pp. 4075-4083.
17. Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C. and Harrison, G. (1998) The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. Blood, 92, pp. 2322-2333.
18. Grimwade, D., Walker, H., Harrison, G., Oliver, F., Chatters, S. and Harrison, C. J. (2001) The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood, 98, pp. 1312-1320.
19. Byrd, J. C., Mrozek, K., Dodge, R. K., Carall, A. J., Edwards, C. G. and Arthur, D. C. (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood, 100, pp. 4325-4336.
20. Liu, S., Mi, Y., Liu, X., Xue, Y., Wang, M. and Bian, S. (2004) Analysis of prognostic factors in Ph-positive adult acute lymphoblastic leukemia. Chin J Hematol, 25, pp. 417-420.
21. Mitelman, F. (1995) ISCN. An International System for Human Cytogenetics Nomenclature, Karger, Basel, Switzerland
22. Berman, E., Helle, G. R., Santorsa, J., McKenzie, S., Gee, T. and Kempin, S. (1991) Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood, 77, pp. 1666-1674.
23. Volger, W. R., Velez-Garcia, E., Weiner, R. S., Flaum, M. A., Bartolucci, A. A. and Omura, G. A. (1992) A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study Group Study. J Clin Oncol, 10, pp. 1103-1111.
24. Schlenk, R. F., Benner, A., Hartmann, F., de Valle, F., Weber, C. and Pralle, H. (2003) Risk-adapted postremission therapy in acute myeloid leukemia: Results of the German multicenter AML HD93 treatment trial. Leukemia, 17, pp. 1521-1528.
25. Mrozek, K., Heerema, N. A. and Bloomfield, C. D. (2004) Cytogenetics in acute leukemia. Blood Rev, 18, pp. 115-136.
26. Byrd, J. C., Dodge, R. K., Carroll, A., Baer, M. R., Edwards, C. and Stamberg, J. (1999) Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol, 17, pp. 3767-3775.
27. Mrozek, K., Heinonen, K., Lawrence, D., Carroll, A. J., Kodaru, P. R. and Rao, K. W. (1997) Adult patients with de novo acute myeloid leukemia and t(9;11)(p22;q23) have a superior outcome to patients with other translocation involving band 11q23: A Cancer and Leukemia Group B study. Blood, 90, pp. 4532-4538.
28. Farag, S. S., Archer, K. J., Mrozek, K., Vardiman, J. W., Carroll, A. J. and Pettenati, M. J. (2002) Isolated trisomy of chromosomes 8, 11, 13, and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461. Int J Oncol, 21, pp. 1041-1051.
29. Mi, Y., Bian, S., Xue, Y., Wang, J., Meng, Q. and Zhao, Y. (2001) Preliminary study on postremission therapy courses in acute myeloid leukemia. Chin J Hematol, 22, pp. 520-523.